Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin

Chest

Volumn 113, Issue 4, 1998, Pages 924-932

  Gutiérrez, Carlos A ^a   Chaparro, Cecilia ^a   Krajden, Mel ^a   Winton, Tim ^a   Kesten, Steven ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Hyperimmune globulin; Lung transplantation; Viremia

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOPROPHYLAXIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VIREMIA;

EID: 0031979183     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.4.924     Document Type: Article

References (42)

1. Rubin RII. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(suppl 7): S754-66
2. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10:638-46
3. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir vs ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57: 876-84
4. Balfour HH Jr, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of acyclovir for the prevention of cytoinegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320:181-87
5. Merigan TC, Renlund DC, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-86
6. Bass EB, Powe XR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone-marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12:179-83
7. Snydman DR, Werner BC, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. New Engl J Med 1987; 317:1049-54
8. Snydman DR. Prevention of cytomegalovirus-associated diseases with inummoglobulin. Transplant Proc 1991; 23(suppl 3): 131-35
9. Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs. immunoglobulin. Arch Surg 1994; 129: 443-47
10. Zamora MR, Fullerton DA, Campbell DN, et al. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients. Transplant Proc 1994; 26(suppl 1):49-51
11. Meyers JD. Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients. Transplant Proc 1991; 3(suppl 3): 139-43
12. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119:84-91
13. Schmidt GE, Horak DA, Niland JC, et al. A randomized controlled trial of prophylactic gauciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-11
14. Singh N, Yu VL, Miele L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994; 120:375-81
15. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A controlled trial. Ann Intern Med 1995; 123:18-26
16. Maurer JR, Snell G, de Hoyos A, et al. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc 1993; 25:1434-35
17. Nicol DL, MacDonald AS, Belitsky P, et al. Reduction bycombination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55:8841-46
18. Martin M, Mañez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58:779-85
19. Bailey TC, Trulock EP, Ettinger NA, et al. Failure of prophylactic ganciclovir to present cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165:548-52
20. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343:749-53
21. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995; 109:49-59
22. Cooper J, Billingham M, Egan T. et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. Heart Lung Transplant 1993; 12:713-16
23. Gleaves CA, Smith TF, Shuster EA, et al. Comparison of standard tube and shell vial culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1985; 21:217-21
24. Storch CA, Buller RS, Bailey TA, et al. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid organ transplant recipients. J Clin Microbiol 1994; 32:997-1003
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 26:457-81
26. Mantel N, Haenzel W. Statistical aspects of the analyses of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48
27. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc 1972; B,74:187-220
28. Grossi P, Minoli L, Pereivalle E, et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995; 59:847-51
29. Winston DJ, Wirin D, Shaked A, et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346:69-74
30. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147:1017-23
31. Gould FK, Freeman R, Taylor CE, et al. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant 1993; 12:695-99
32. Chamberlain DW. Lung transplantation pathology: allograft evaluation. In: Patterson GA, Courand L, eds. Lung transplantation. Current Topics in General Thoracic Surgery: An International Series (vol 3). Amsterdam: Elsevier Science, 1995; 320-21
33. Kelly JL, Albert RK, Wood DE, et al. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995; 59:1144-47
34. Goodrich JM, Mori M, Gleaves C, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-07
35. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162:373-80
36. Egan JJ, Barber L, Lomax J, et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995; 50:9-13
37. Sackett DL, Haynes RB, Guyatt GH, et al. The interpretation of diagnostic data. In: Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown, 1991; 69-152
38. Keenan RJ, Lega ME, Dummer S, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51:433-38
39. Storch GA, Ettinger NA, Ockner D, et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients. J Infect Dis 1993; 168: 150-56
40. Drew WL, Miner RC, Busch DF, et al. Prevalent of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991: 163:716-19
41. Boivin G, Erice A, Crane DD, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168:332-35
42. Sarris GE, Smith JA, Shumway E, et al. Long-term results of combined heart-lung transplantation: the Stanford experience. J Heart Lung Transplant 1994; 13:940-49